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ABSTRACT 
Magnesium (Mg) has been developed as a drug with various clinical uses. Mg is a key cation in physiological 
processes, and the homeostasis of this cation is crucial for the normal function of body organs. Magnesium sulfate 
(MgSO4) is a mineral pharmaceutical preparation of magnesium that is used as a neuroprotective agent. One ra-
tionale for the frequent use of MgSO4 in critical care is the high incidence of hypomagnesaemia in intensive care 
unit (ICU) patients. Correction of hypomagnesaemia along with the neuroprotective properties of MgSO4 has 
generated a wide application for MgSO4 in ICU. 
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INTRODUCTION 
Magnesium (Mg) is one of the most 
abundant cations in the body, and is also a 
drug with numerous clinical applications. The 
body usually contains up to 28 g of Mg 
(Wacker and Parisi, 1968). Most of the Mg is 
present as an intracellular cation. Of total Mg 
in the body, 53 % accumulates in bones, 27 % 
in muscular tissues, 19 % in soft tissues, 
0.5 % in red blood cells, and 0.3 % in blood 
serum (Facchinetti et al., 1991). Half of this 
Mg is available as free ion and not bound to 
albumin or anions (Jahnen-Dechent and 
Ketteler, 2012). Increase or decrease in serum 
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Mg level is associated with impaired body he-
mostasis and disorders of different organs 
(Kingston et al., 1986). Hypomagnesaemia is 
described as serum Mg levels below 1.7 
mg/dL, while hypermagnesaemia occurs 
when the total serum Mg level is higher than 
2.6 mg/dL (Kingston et al., 1986; Soesan et 
al., 2000). 
 
PHYSIOLOGICAL ROLES OF MG 
Magnesium is a vital element that is di-
rectly or indirectly involved in the 
physiological processes (Aikawa, 1980). 
Magnesium is an essential co-factor for the 
enzymatic reactions (Aikawa, 1980). This 
element is particularly involved in the storage 
and transfer of the energy (Noronha and 
Matuschak, 2002; Reinhart, 1988). Also, Mg 
regulates glycolysis-related enzymes 
(Fawcett et al., 1999). Mg activates a lot of 
enzymatic systems that are essentially neces-
sary in the metabolism of energy. Magnesium 
is a calcium antagonist that acts via regulating 
intracellular calcium availability (Romani, 
2011). Calcium metabolism and transporta-
tion has crucial roles in cardiac function, mus-
cular contraction, blood pressure regulation 
and neuronal activity (Akhtar et al., 2011; 
Noronha and Matuschak, 2002).  
Influx and efflux of Mg plays an 
important role in different transcellular trans-
ports (Kolte et al., 2014). Magnesium defi-
ciency induces a systemic stress to respond 
during activation of neuroendocrine pathways 
(Mazur et al., 2007); it has been implicated in 
the pathophysiology of several diseases and 
reported to be related to increased mortality in 
ICU patients (Zafar et al., 2014). A defect in 
any part of the transcellular transports may 
lead to different diseases such as pre-eclamp-
sia, Parkinson's disease, atrial fibrillation and 
anoxic brain injury (Kolte et al., 2014). Mag-
nesium has analgesic properties that are due 
to N-methyl-D-aspartate (NMDA) receptor 
blocking action (Akhtar et al., 2011). Other 
physiological roles of Mg include: (1) estab-
lishing the electrical potential across cell 
membranes; (2) involvement in intermediary 
metabolism; (3) involvement in protein and 
nucleic acid synthesis; (4) exerting depressant 
effect at the synapse as Mg affects channels 
on the cardiac and smooth muscles; (5) cell 
cycle regulation; (6) mitochondrial functions 
control; (7) maintaining stability of cell 
membranes, and (8) supporting cytoskeletal 
integrity (Aikawa, 1980; Dubé and Granry, 
2003; Fawcett et al., 1999; Golf et al., 1993; 
Gordon, 1963; Mubagwa et al., 2007; Nadler 
and Rude, 1995; Simpson and Knox, 2004; 
Volpe and Vezu, 1993; Wacker and Parisi, 
1968; White and Hartzell, 1989). 
 
MAGNESIUM DEFICIENCY IN ICU  
One of the key reasons for the wide use of 
Mg in critical care is the high prevalence of 
hypomagnesaemia in ICU patients (Noronha 
and Matuschak, 2002; Tong and Rude, 2005). 
Around 90 % of ICU patients under surgery 
and 65 % of ICU patients under drug therapy 
commonly experience hypomagnesaemia 
(Koch et al., 2002). Hypomagnesaemia is cor-
related with poor prognosis and high mortal-
ity rate in critically ill patients (Dabbagh et 
al., 2006). 
Noronha and Matuschak in 2009 de-
scribed major causes of Mg deficiency in ICU 
patient as: (1) reduction of intestinal absorp-
tion of Mg, (2) increased loss of Mgbyrenal 
route, and (3) compartmental redistribution 
(Noronha and Matuschak, 2002). The most 
common gastrointestinal (GI) diseases with 
Mg loss include intestinal malabsorption 
syndromes, inadequate Mg intake, re-feeding 
syndrome, chronic diarrhea, short bowel 
syndrome, fistulae in the intestinal and biliary 
system, and acute pancreatitis (Booth et al., 
1963; Edmondson et al., 1952; Gordon, 1963; 
Hall and Joffe, 1973; Martin et al., 2009). 
Long-term use of Proton Pump Inhibitors 
(PPIs) has also been reported to block intesti-
nal absorption of Mg. The mechanism of this 
action is an increase in the intestinal lumen 
PH that proceeds to the reduction of TRPM 
6/7 channel affinity for Mg (Thongon and 
Krishnamra, 2011; William et al., 2014). 
Intravenous Mg supplementation rapidly 
increases serum Mg level following long-
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term use of PPIs and subsequent hypomagne-
saemia. PPIs affect intestinal epithelial cell 
locally. Oral Mg is not effective in PPI’s in-
duced hypomagnesaemia. Discontinuation of 
PPI use will resultsin quick normalization of 
serum Mg levels (Mackay and Bladon, 2010; 
William and Danziger, 2016). 
Renal excretion is an important cause of 
Mg loss in ICU patients. Interstitial 
nephropathy, post-obstructive diuresis, acute 
tubular necrosis (diuretic phase), post-renal 
transplantation and drug-induced Mg wasting 
(Aminoglycosides, Amphotericin B, Cis-
platin, Colony-stimulating factor therapy, 
Cyclosporine A, Loop and thiazide diuretics, 
Pentamidine) are reasons for renal Mg loss 
(Barton et al., 1984, 1987; Hellman et al., 
1962; Jones et al., 1966; Kingston et al., 1986; 
Knochel, 1977; Lim and Jacob, 1972; Martin 
et al., 2009; Noronha and Matuschak, 2002; 
Shah et al., 1990; Shah and Kirschenbaum, 
1991; von Vigier et al., 2000). 
Causes of Mg loss due to redistribution of 
Mg and endocrine disorders include acute 
respiratory alkalosis, administration of 
epinephrine, alcoholic ketoacidosis, blood 
transfusion, diabetic ketoacidosis, hyperaldo-
steronism, hyperparathyroidism, hyperthy-
roidism, hungry bone syndrome, and 
syndrome of inappropriate antidiuretic 
hormone (al-Ghamdi et al., 1994; Aziz et al., 
1996; England et al., 1992; Martin et al., 
2009; McLellan et al., 1984; Shane and Flink, 
1991; Whyte et al., 1987). Other causes 
include cardiopulmonary bypass, hypophos-
phatemia (chronic alcoholism), hypercal-
cemia/hypercalciuria, excessive sweating and 
severe burns (al-Ghamdi et al., 1994; 
Kingston et al., 1986; Martin et al., 2009; 
Weglicki and Phillips, 1992).  
 
CLINICAL MANIFESTATIONS OF 
HYPOMAGNESAEMIA IN THE ICU 
The symptoms of hypomagnesaemia start 
when serum Mg levels fall below 1.2 mg/dL 
(Kingston et al., 1986). These symptoms af-
fect different body organs and depend on the 
rate of deficiency of ionized Mg (Brenner and 
Rector, 1991). However, most cases of 
hypomagnesaemia in intensive care are 
asymptomatic (Soesan et al., 2000). Clinical 
manifestations of hypomagnesaemia in ICU 
patients include muscle cramps, tremor, 
weakness, hyperreflexia, positive Trousseau 
or Chvostek sign, carpopedal spasm, tetany, 
nystagmus, vertigo, aphasia, hemiparesis, 
delirium, choreoathetosis, supraventricular 
arrhythmias, ventricular arrhythmias, tor-
sades de pointes, electrolyte disturbance 
(hypocalcemia, hypokalemia, or both), 
hypertension, coronary vasospasms, and 
bronchial airway constriction. Severe hypo-
magnesaemia may cause generalized tonic-
clonic seizures (Burch and Giles, 1977; Iseri 
et al., 1989; Ralston et al., 1989; Ryzen et al., 
1985; Tzivoni et al., 1988; Wacker, 1962; 
Watanabe and Dreifus, 1972). 
 
MAGNESIUM SULFATE IN ICU 
Numerous roles for magnesium in critical 
care medicine have been suggested (Noronha 
and Matuschak, 2002). Deficiency of Mg is 
common in hospitalized patients, and is fre-
quently reported in admitted ICU patients 
(Koch et al., 2002; Ryzen et al., 1985). 
Management of patients in ICU is somehow 
complicated and depends on the conditions of 
every patient (Honarmand et al., 2012). It has 
been suggested to employ an established 
protocol as a base to define a moderate dose 
of Mg that is safe over the years in ICU 
(Hebert et al., 1997).  
In 1906, for the first time, magnesium sul-
fate (MgSO4) was used to prevent eclamptic 
seizures in Germany (Horn, 1906). Magne-
sium is replaced intravenously with MgSO4 
when hypomagnesaemia is severe (Ryzen et 
al., 1985). MgSO4 is the essential preparation 
of intravenous Mg. Magnesium sulfate, usu-
ally known as Epsom salt, is an ordinary min-
eral pharmaceutical preparation of Mg that is 
used both externally and internally. Both Mg 
and sulfate absorb through the skin to recover 
blood levels (Noronha and Matuschak, 2002; 
Ignatavicius and Workman, 2015). A number 
of authors have described Mg as “the forgot-
ten electrolyte” (Elin, 1994; Gonzalez et al., 
2013). Hypomagnesaemia is a significant but 
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underdiagnosed electrolyte imbalance 
(Gonzalez et al., 2013). MgSO4 has been used 
during the 20th century for eclamptic seizures’ 
prevention (Lazard, 1925; Pritchard, 1955), 
and continues to be used widely.  
Numerous mechanisms of action have 
been suggested for magnesium including (1) 
vasodilatory action, (2) blood-brain barrier 
(BBB) protection, (3) reduction of cerebral 
edema, and (4) central anticonvulsant action 
(Aali et al., 2007).  
 
CLINICAL APPLICATION OF  
MAGNESIUM SULFATE IN ICU 
1. Acute asthma 
Asthma has been described as a chronic 
inflammatory disorder of the airways with an 
increase of bronchial responsiveness to a va-
riety of stimuli. It is often reversible, either 
spontaneously or with treatment (Bateman et 
al., 2008). 
Standard treatments for asthma crisis in-
clude bronchodilators (short-acting), agonists 
of β2-receptors, inhaled ipratropium bromide, 
corticosteroids, anticholinergic drugs and 
general managements (Bateman et al., 2008). 
Researchers have suggested MgSO4 as a treat-
ment option for patients who are resistant to 
standard therapy (Bateman et al., 2008; 
Gontijo-Amaral et al., 2007; Jones and 
Goodacre, 2009; Kew et al., 2014). Life-
threatening conditions like severe asthma at-
tacks require intensive medical care. The 
beneficial effects of MgSO4 have been shown 
in children and adult patients with severe 
asthma in the ICU (Boonyavorakul et al., 
2000; Daengsuwan and Watanatham, 2016; 
Griffiths and Kew, 2016; Kew et al., 2014; 
Kokturk et al., 2005; Rowe, 2013; Rowe and 
Camargo, 2008; Rower et al., 2017; Singh et 
al., 2008). 
Mechanisms of Mg action for the 
management of severe asthma include: (1) 
reduction of intracellular calcium level 
(blockade of calcium entry, calcium release 
and activation of Na+-Ca2+ pumps), (2) 
muscle relaxation (inhibition of myosin and 
calcium interaction), (3) reduction of inflam-
matory mediators (inhibition of degranulation 
of mast cells and T-cells stabilization), (4) 
depression of the irritability of muscle fibers, 
and (5) inhibition of prostacyclin and nitric 
oxide synthesis. These mechanisms lead to a 
reduction in the severity of asthma (Gontijo-
Amaral et al., 2007; Rowe, 2013). 
MgSO4 is used via intravenous and inha-
lation routes for the management of acute 
asthma (Shan et al., 2013). Use of MgSO4 
through intravenous route in adult and 
children patients improves respiratory 
function (Boonyavorakul et al., 2000; Daeng-
suwan and Watanatham, 2016; Griffiths and 
Kew, 2016; Kew et al., 2014; Kokturk et al., 
2005; Rowe, 2013; Rowe and Camargo, 
2008; Rower et al., 2017; Singh et al., 2008). 
In some countries, the intravenous form of 
MgSO4 is broadly used as an adjunctive 
therapy for severe acute asthma, especially in 
patients not responding to initial treatments 
(British Thoracic Society Scottish Inter-
collegiate Guidelines, 2008; Jones and 
Goodacre, 2009). Unlike adults, in children 
MgSO4 has a significant effect on hospital 
admission (Ciarallo et al., 2000, 1996; 
Gurkan et al., 1999; Porter et al., 2001; 
Scarfone et al., 2000). The impact of MgSO4 
on forced expiratory volume in 1 second 
(FEV1) and peak expiratory flow rate (PEFR) 
were assessed in different clinical trials 
(Bessmertny et al., 2002; Bloch et al., 1995; 
Boonyavorakul et al., 2000; Devi et al., 1997; 
Gallegos-Solorzano et al., 2010; Green and 
Rothrock, 1992; Hughes et al., 2003; Mahajan 
et al., 2004; Silverman et al., 2002; Tiffany et 
al., 1993). In children, brief infusion and max-
imum weight-based dosage of MgSO4 have 
been suggested for the management of se-
verely ill asthmatic patients in the ICU 
(Egelund et al., 2013; Liu et al., 2016). Up to 
2.5 gram of Mg loading dose with β-agonist 
and corticosteroid (methylprednisolone, 
hydrocortisone, and dexamethasone) were re-
ported to be efficacious in the management of 
asthma (British Thoracic Society Scottish 
Intercollegiate Guidelines, 2008). Ipra-
tropium, aminophylline, theophylline and 
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ephedrine are additional drugs in the manage-
ment of acute asthma (Bloch et al., 1995; Devi 
et al., 1997; Green and Rothrock, 1992; Singh 
et al., 2008; Tiffany et al., 1993). However, in 
contrast to intravenous MgSO4, the effect of 
the inhaled form remains controversial. Up to 
500 mg MgSO4 for each dose of nebulization 
has been used in several clinical trials 
(Aggarwal et al., 2006; Ahmed et al., 2013; 
Bessmertny et al., 2002; Chande and Skoner, 
1992; Gallegos-Solorzano et al., 2010; 
Gandia et al., 2012; Hill et al., 1997; Hughes 
et al., 2003; Kokturk et al., 2005; Mangat et 
al., 1998; Nannini and Hofer, 1997; Nannini 
et al., 2000; Rolla et al., 1987; Zandsteeg et 
al., 2009). Respiratory functions and hospital 
admission were assesed in all studies and, 
similar to intravenous MgSO4 therapy, β-
agonists and corticosteroids were used in all 
patients (Aggarwal et al., 2006; Ahmed et al., 
2013; Chande and Skoner, 1992; Gandia et 
al., 2012; Hill et al., 1997; Mangat et al., 
1998; Nannini and Hofer, 1997; Nannini et 
al., 2000; Rolla et al., 1987; Zandsteeg et al., 
2009). In one study, nebulized MgSO4 was 
compared to nebulized salbutamol (Mangat et 
al., 1998). The authors showed that there is no 
significant difference between the broncho-
dilatory effect of nebulized MgSO4 and sal-
butamol in the management of acute asthma 
(Gonzalez et al., 2013). In 2016, Ling and col-
leagues reported that nebulized MgSO4 is not 
useful to improve pulmonary function or 
reduce the number of patients admitted to the 
hospital in adults with acute asthma (Ling et 
al., 2016). In children, treatment with 
nebulized magnesium sulfate showed no sig-
nificant effect on respiratory function or hos-
pital admission and further treatment (Su et 
al., 2016). Adverse events have been 
occasionally reported in the clinical trials, but 
the most common adverse reactions with 
MgSO4 are cardiac arrhythmia, confusion, 
drowsiness, flushing, hypotension, loss of 
deep tendon reflexes, muscle weakness, nau-
sea, respiratory depression, thirst, and vomit-
ing. Rarely, administration of MgSO4 can lead 
to cardiac arrest and coma (Martindale and 
Westcott, 2008).  
2. Magnesium sulfate as a  
neuroprotective agent 
MgSO4 has been well documented to be 
beneficial in the management of nervous sys-
tem injuries especially in the ICU. These in-
juries include stroke, aneurysmal subarach-
noid hemorrhage (ASAH), and traumatic 
brain injuries (Afshari et al., 2013; Akdemir 
et al., 2009; Bradford et al., 2013; Chan et al., 
2005; Chen et al., 2015; Chen and Carter, 
2011; Dabbagh et al., 2006; Dorhout Mees et 
al., 2012; Friedlich et al., 2009; Gao et al., 
2013; Gonzalez-Garcia et al., 2012; Hassan et 
al., 2012; James et al., 2009; Jiang et al., 2017; 
Johnson et al., 1993; Kahraman et al., 2003; 
Kidwell et al., 2009; Kumar et al., 2015; 
Lamers et al., 2003; Lampl et al., 2001; 
Mirrahimi et al., 2015; Mousavi et al., 2004, 
2010; Muir and Lees, 1995; Muir et al., 2004; 
Muroi et al., 2008; Rahimi-Bashar et al., 
2017; Rinosl et al., 2013; Saver et al., 2015; 
Selvaraj and Syed, 2014; Singh et al., 2012; 
Sleeswijk et al., 2008; Stippler et al., 2006; 
van den Bergh et al., 2005; van Norden et al., 
2005; Veyna et al., 2002; Wang et al., 2012; 
Westermaier et al., 2010; Wong et al., 2010; 
Zafar et al., 2014; Zhao et al., 2016; Zhu et 
al., 2004).  
MgSO4 and Aneurysmal Subarachnoid Hem-
orrhage (ASAH) 
Several studies have been performed on 
the efficacy and dosage of MgSO4 in ASAH 
in the last two decades (Afshari et al., 2013; 
Akdemir et al., 2009; Bradford et al., 2013; 
Chen et al., 2015; Chen and Carter, 2011; 
Dabbagh et al., 2006; Dorhout Mees et al., 
2012; Hassan et al., 2012; Jiang et al., 2017; 
Kahraman et al., 2003; Kidwell et al., 2009; 
Kumar et al., 2015; Mousavi et al., 2010; 
Muir and Lees, 1995; Muir et al., 2004; Muroi 
et al., 2008; Saver et al., 2015; Selvaraj and 
Syed, 2014; Singh et al., 2012; Sleeswijk et 
al., 2008; Stippler et al., 2006; van den Bergh 
et al., 2005; van Norden et al., 2005; Veyna et 
al., 2002; Wang et al., 2012; Westermaier et 
al., 2010; Wong et al., 2010; Zafar et al., 
2014; Zhao et al., 2016; Zhu et al., 2004). Dif-
ferent doses of MgSO4 have been suggested 
for neuroprotection. Veyna and colleagues 
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used MgSO4 in 20 ASAH patients and 
showed that high dose of Mg is safe and 
efficient and can maintain serum Mg levels in 
the range of 4-5.5 mg/dL. Their study was 
focused on vasospasm, middle cerebral artery 
(MCA) velocity and Glasgow Outcome Scale 
(GOS). The findings showed better outcome 
in patients with ASAH 90 days post-hemor-
rhage, but they did not find a significant dif-
ference in GOS between the control and treat-
ment groups (Veyna et al., 2002). Also, van 
Norden et al. (2005) showed that treatment 
with MgSO4 at a dose of 64 mmol/day will 
result in 1-2 mmol/L of serum Mg level with-
out any side effect. Studies by Van der Bergh 
and colleagues (2005) revealed that MgSO4 
delays cerebral ischemia. They used Rankin 
score to measure outcomes in the patients. 
Stippler reported the efficacy of Mg in the 
management of SAH and improving the Ran-
kin score. The mechanism of Mg efficacy in 
SAH was suggested to involve a significant 
reduction in vasospasm (Stippler et al., 2006). 
High dose of MgSO4 was also suggested to be 
prophylactic and associated with better out-
comes in SAH patients (Muroi et al., 2008). 
MgSO4 can increase ischemic tolerance in the 
nervous system at the time of hypo-perfusion, 
attenuate vasospasm and decrease outcomes 
in patients with ASAH (Bradford et al., 2013; 
Chen and Carter, 2011; Westermaier et al., 
2010). Despite these findings on the 
beneficial role of MgSO4 in ASAH, in three 
studies authors did not suggest this drug for 
ASAH or did not find any efficacy in the 
patients (Akdemir et al., 2009; Dorhout Mees 
et al., 2012; Wong et al., 2010). Friedlich et 
al. (2009) reported that MgSO4 at a dose of 
0.6 g/hour has a prophylactic effect on cere-
bral vasospasm in the first 72 hours in a 
patient with ASAH. Overall, MgSO4 seems to 
be beneficial in the management of ASAH.  
MgSO4 and stroke 
The use of MgSO4 24 hours post-stroke 
shows a significant decrease in the infarct vol-
ume based on the findings of MRI (Kidwell et 
al., 2009). Saver and colleagues performed a 
study on 1700 stroke patients in 2015 (Saver 
et al., 2015). In their study, GCS, NIHSS and 
Barthel index were improved in the treatment 
group receiving MgSO4 compared with the 
control group (Veyna et al., 2002). Singh et 
al. (2012) showed neuroprotective properties 
of Mg in the stroke patients that received in-
travenous MgSO4 in comparison to the con-
trol group. Afshari and colleagues showed a 
significant effect of MgSO4 in decreasing the 
length of hospital stay in stroke patients 
(Afshari et al., 2013). The significant effect of 
Mg on Barthel index, the length of hospital 
stays and recovery in 30 days post-stroke in 
the patients was reported by Lampl and col-
leagues (2001). It was also suggested that one 
gram of MgSO4 daily decreases mortality rate 
in the non-cardiac ICU patients (Dabbagh et 
al., 2006). Concurrent use of MgSO4 and 
nimesulide, and MgSO4 alone, has been re-
ported to reduce the infarct volume in an ani-
mal model of stroke (Wang et al., 2012; Zhu 
et al., 2004). 
Effect of MgSO4 on biomarkers in 
different neuropathies has been assessed in 
several studies (Bharosay et al., 2012; Chan et 
al., 2005; Friedlich et al., 2009; Gao et al., 
2013; Gonzalez-Garcia et al., 2012; Hassan et 
al., 2012; James et al., 2009; Johnson et al., 
1993; Lamers et al., 2003; Mirrahimi et al., 
2015; Rahimi-Bashar et al., 2017; Rinosl et 
al., 2013). MgSO4 was shown to decrease 
S100B levels with little side effects (Hassan 
et al., 2012). The increase of biomarkers like 
S100B and S-SNE has been reported with se-
rum Mg levels below 1.2 mmol/L, and is as-
sociated with poor outcomes and a higher rate 
of mortality in patients with stroke (James et 
al., 2009; Mirrahimi et al., 2015). The 
decrease of these biomarkers may be corre-
lated with an increase of Barthel index (James 
et al., 2009). S100B has more sensitivity and 
specify than S-NSE (Gonzalez-Garcia et al., 
2012; Lamers et al., 2003). Increase in S100B 
levels is associated with an increase in infarct 
size and NIH stroke score (Jauch et al., 2006; 
Mizukoshi et al., 2013). Increase in serum 
NSE levels has also been reported to be asso-
ciated with an increase in post-stroke disabil-
ity (Bharosay et al., 2012).  
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Gao and colleagues reported that 5 to 
10 mmol/L of intravenous MgSO4 decreases 
inflammatory biomarkers such as nitric oxide, 
prostaglandin E2, interleukin 1β and tumor 
necrosis factor-α (Gao et al., 2013). Concur-
rent use of neuroprotective agents and throm-
bolytic therapy is a promising treatment for 
acute ischemic stroke (Chen et al., 2002; 
Ovbiagele et al., 2003). 
Mg and Traumatic brain injuries (TBI) 
TBI is an important health problem with 
high a mortality and morbidity rate (Maas et 
al., 2008). Studies on animal models have 
shown that Mg can increase the survival of 
neurons in cerebral ischemia and traumatic 
brain injury (Schanne et al., 1993; Sirin et al., 
1998).  
Numerous studies have reported that Mg 
plays an important role in the prevention and 
treatment of central nervous system (CNS) in-
juries. Magnesium protects neurons from is-
chemic injuries and supports neuronal sur-
vival following TBI with different mecha-
nisms such as: (1) blocking NMDA channels, 
(2) inhibition of presynaptic excitatory neuro-
transmitters, (3) inhibition of voltage-gated 
calcium channels, and (4) potentiation of pre-
synaptic adenosine. Moreover, Mg can relax 
vascular smooth muscles and enhance cere-
bral blood flow. Serum total and ionized Mg 
levels are reduced after head injuries 
(McIntosh, 1993; Memon et al., 2009). The 
entrance of Mg into the CNS is dependent on 
the integrity of the BBB. In animal models, 
traumatic head injuries will facilitate entrance 
of Mg into the CNS for at least 24 hours 
(Habgood et al., 2007; Heath and Vink, 
1998). The permeability of BBB in personal 
traumatic head injuries is not always present 
(Miller and D'Ambrosio, 2007). 
 
3. MgSO4 in other patients admitted to 
the ICU 
The beneficial effect of MgSO4 in ICU 
patients was described and assessed by 
researchers using different assessment 
methods (SOFA score, GCS, Rankin score, 
RASS score, APACHE score, NIH stroke 
scores, Barthel index, infarction volume, 
sepsis, tissue oxygenation index, mechanical 
ventilation and intubation requirement, length 
of hospital and ICU stay, and mortality) 
(Afshari et al., 2013; Chen et al., 2015; 
Dabbagh et al., 2006; Jiang et al., 2017; 
Kidwell et al., 2009; Kumar et al., 2015; 
Mousavi et al., 2010; Muir and Lees, 1995; 
Saver et al., 2015; Singh et al., 2012; Wang et 
al., 2012; Zafar et al., 2014; Zhao et al., 2016; 
Zhu et al., 2004). 
The neuroprotective effect of MgSO4 in 
diffuse axonal injury has been shown by Zhao 
et al. (2016). The intervention group in the re-
ferred study showed higher Glasgow coma 
scale (GCS) and lower serum neuron-specific 
enolase level (S-NSE), but the length of ICU 
stay and mortality did not differ between con-
trol and intervention groups (Habgood et al., 
2007). The presence of hypomagnesaemia in 
374 ICU patients was reported by Chen and 
colleagues. Their results showed that hypo-
magnesaemia was correlated with increased 
length of ICU stay, SOFA score and mortality 
rate (Chen et al., 2015). The mortality rate in 
the ICU patients with hypomagnesaemia was 
reported as 74 % in comparison with 36 % in 
patients with normal serum Mg levels (Zafar 
et al., 2014).  
Hypomagnesaemia had a higher incidence 
in the alcoholic patients and patients with di-
abetes mellitus, sepsis, hepatic cirrhosis and 
chronic kidney disease. Higher need to 
mechanical ventilation, increase in the length 
of mechanical ventilation, increase in the risk 
of sepsis, higher APACHE score, decrease in 
NIHS score, decrease in serum albumin level 
and hypokalemia were also reported in these 
patients (Jiang et al., 2017; Kumar et al., 
2015; Mousavi et al., 2004, 2010; Muir and 
Lees, 1995). MgSO4 cannot improve the 
strength of respiratory muscles in the criti-
cally ill patients under mechanical ventilation 
(Johnson et al., 1993). Serum Mg level is a 
key factor determining the outcome of the 
patients in ICU (Rahimi-Bashar et al., 2017). 
The normal level of serum Mg was associated 
with shorter time under mechanical ventila-
tion and intubation and decreased ICU stay 
(Lampl et al., 2001). 
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In patients admitted to the ICU after major 
abdominal surgery, serum Mg level should be 
checked daily because two-thirds of patients 
after abdominal surgery are diagnosed with 
hypomagnesaemia (Selvaraj and Syed, 2014). 
As stated earlier, hypomagnesaemia is widely 
observed in the ICU, thus Mg replenishment 
should be considered in patients admitted to 
the ICU. For this reason, MgSO4 is an 
important drug in the ICU. MgSO4 can in-
crease brain tissue oxygenation index by 
34 % after cerebral artery occlusion (Chan et 
al., 2005).  
Electrolyte imbalance following hypo-
magnesaemia has been reported by research-
ers in the ICU (Buckley et al., 2010; Elin, 
1994; Faber et al., 1994; Gonzalez et al., 
2013; Sedlacek et al., 2006). Hypomagnesae-
mia can lead to a 2-3-fold increased mortality 
in ICU, and is one of the main causes of 
hypokalemia and hypocalcemia. It is also as-
sociated with hyponatremia and hypo-
phosphatemia (Elin, 1994; Gonzalez et al., 
2013; Sedlacek et al., 2006). Mg has a major 
role in the transport of potassium, and simul-
taneous correction of hypomagnaesemia and 
hypokalemia is mandatory (Sedlacek et al., 
2006). Gupta et al. (2009) showed that in a 
critically ill patient, administration of potas-
sium and calcium is not sufficient to correct 
hypocalcemia and hypokalemia. Correction 
of hypomagnesaemia and control of Mg level 
in serum is highly recommended in patients 
with hypocalcemia and hypokalemia (Gupta 
et al., 2009). 
Magnesium sulfate was suggested by 
some authors to be efficacious in cardiac 
operations such as atrial fibrillation (AF), 
coronary artery bypass surgery and heart 
valve surgeries (Gu et al., 2012; Lee et al., 
2016; Lip, 2016; Mazurek and Lip, 2017; 
Talkachova et al., 2016; Treggiari-Venzi et 
al., 2000). Low serum Mg level and older age 
have been reported as risk factors for AF 
(Treggiari-Venzi et al., 2000). Atrial fibrilla-
tion is also one of the risk factors for ischemic 
stroke (Talkachova et al., 2016). The role of 
MgSO4 for the management of AF is contro-
versial. Use of intravenous MgSO4 without 
any other drugs in 16 patients was able to re-
turn heart rhythm to normal sinus rhythm af-
ter atrial fibrillation crisis (Sleeswijk et al., 
2008). Kaplan et al. reported that MgSO4 
alone is not useful in the management of AF 
(Kaplan et al., 2003). Concurrent use of 
MgSO4 with amiodarone in a post-operative 
patient with thorax surgery was reported to be 
beneficial for the prophylaxis against AF 
(Khalil et al., 2012). In subjects with coronary 
bypass surgeries, MgSO4 was reported to re-
duce the risk of AF by 36 percent (Gu et al., 
2012). Administration of intravenous MgSO4, 
pre-operatively, post-operatively and during 
the heart valve surgery, decreased the risk of 
AF (Laiq et al., 2013). 
 
CONCLUSION 
Despite the controversial views on the ef-
fects of MgSO4 as a neuroprotective agent, 
current evidence suggests that MgSO4 is an 
important part of the management of ICU pa-
tients (Table 1). Magnesium sulfate is essen-
tial to correct hypomagnesaemia and can de-
crease mortality rate, decrease the length of 
ICU stay, and is associated with reduced out-
comes in patients admitted to the ICU. Be-
cause of the high prevalence of hypo-
magnesaemia and necessity of intravenous 
MgSO4 therapy in the ICU, serum Mg levels 
should be checked on a daily basis. 
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Table 1: Summary of clinical studies evaluating the role of magnesium sulfate (MgSO4) in critically ill 
patients 
Study/References Study  
population 
no. of  
patients 
Associ-
ated  
Diseases 
MgSO4 dosage Outcome/results 
Kaplan et al., 2003 200 coronary 
artery by-
pass graft-
ing opera-
tions 
3 g in 100 ml of normal 
saline infused preopera-
tively and at postoperative 
days 0, 1, 2, and 3 
magnesium sulfate 
alone is not effec-
tive for the prophy-
laxis of atrial fibrilla-
tion (AF) 
Khalil et al., 2012 438 undergoing 
lobectomy 
80 mg/kg magnesium sul-
fate over 30 min preoper-
atively and then infusion 8 
mg/kg/h for 48 hrs 
decrease rate of AF 
post operatively, 
but amiodarone 
had better outcome 
Laiq et al., 2013 100 cardiac 
valvular 
surgery 
40 mg/kg in 100 ml of nor-
mal saline infused pre-
operatively in 30 minutes 
good pre, intra and 
post-operative pre-
vention of AF in 
studied patients 
Sleeswijk et al., 
2008 
29 critically Ill 
patients 
with new-
onset AF 
0.037 g/kg body weight in 
15 minutes followed by 
continuous infusion 0.025 
g/kg body weight/h 
less than half of pa-
tients respond well 
to MgSO4 therapy 
Treggiari-Venzi et 
al., 2000 
155 elective 
coronary 
bypass 
grafting 
4 g of MgSO4 per 24 hrs MgSO4 had no 
prophylaxis of AF 
Akdemir et al., 
2009 
83 Aneurys-
mal Sub-
arachnoid 
Hemor-
rhage 
(ASAH) 
20 mmol MgSO4 was ad-
ministered during a period 
of 30 minutes, then con-
stant infusion of 64 mmol 
every 24 hrs as required 
(based on daily serum 
magnesium levels) until 
10 days 
no significant role in 
the prevention of 
cerebral vaso-
spasm 
Hassan et al., 2012 30 ASAH 16 mmol of MgSO4 was 
administered over 20 min; 
followed by a continuous 
infusion of 65 mmol per 
day for 14 days after oc-
clusion of the aneurysm 
no difference in out-
come between 
MgSO4 group and 
control, but de-
crease of S100B 
protein was ob-
served 
Dorhout Mees et 
al., 2012 
1204 ASAH 64 mmol per day MgSO4 does not 
improve outcome 
Muroi et al., 2008 58 ASAH 16 mmol in a 150 mL of 
Ringer's lactate adminis-
tered over 15 minutes, fol-
lowed by a continuous in-
fusion of 65 mmol per day 
for 12 days 
High dose of 
MgSO4 may be 
beneficial to reduce 
poor outcome. Side 
effects observed in 
12 days of admin-
istration 
van Norden et al., 
2005 
94 ASAH continuous infusion of  
64 mmol per day until  
14 days 
64 mmol of MgSO4 
per day maintained 
Mg serum level be-
tween 1-2 mmol/L 
without side effect 
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Study/References Study  
population 
no. of  
patients 
Associ-
ated  
Diseases 
MgSO4 dosage Outcome/results 
Stippler et al., 
2006 
76 ASAH 12 grams of MgSO4 in 
500 ml normal saline in-
travenously daily for 12 
days 
MgSO4 is beneficial 
as prophylaxis for 
cerebral vaso-
spasm (should initi-
ated in 48 hrs after 
ASAH) 
van den Bergh et 
al., 2005 
283 ASAH 64 mmol/L per day for 
14 days 
MgSO4 reduced de-
layed cerebral is-
chemia and 
showed better out-
come 
Veyna et al., 2002 40 ASAH 6 g in a 250 ml Normal  
saline over 30 minutes, 
followed by continuous i 
nfusion at 2 g/h 
Better Glasgow 
Outcome Scale in 
patients treated 
with MgSO4 without 
side effect 
Westermaier et al., 
2010 
110 ASAH bolus of 16 mmol, fol-
lowed by continuous  
infusion of 8 mmol/h 
MgSO4 attenuates 
vasospasm and re-
duces cerebral is-
chemic events 
Wong et al., 2010 327 ASAH bolus of 20 mmol over 30 
minutes, followed by infu-
sion of 80 mmol/day up to 
14 days 
No clinical benefit 
of MgSO4 IV ad-
ministration 
Chan et al., 2005 18 ASAH magnesium 20 mmol over 
10 min followed by an in-
fusion of 4 mmol/h 
magnesium en-
hances tissue oxy-
genation and atten-
uates hypoxia 
Zhao et al., 2016 128 severe  
diffuse  
axonal  
injury 
Bolus of 250 µmol/kg 
magnesium sulfate, fol-
lowed by 750 µmol/kg 
magnesium sulfate daily 
for 3–5 days 
Significant improve-
ment of diffuse ax-
onal injury outcome 
Afshari et al., 2013 107 acute  
ischemic 
stroke 
4 g in 50 mL normal saline 
over a 15-minute period 
and 16 g in 100 mL over a 
24 h period 
Significant recovery 
in patients that re-
ceived MgSO4 
Lampl et al., 2001 44 acute 
stroke  
4 g in100 mL normal sa-
line over a 15 minute pe-
riod, followed by 35 g in 
1000 mL over a 24 h pe-
riod for 5 days 
Significant positive 
effect on the out-
come 
Muir et al., 2004 2589 acute 
stroke 
Bolus of 16 mmol MgSO4 
intravenously over 15 min 
and then 65 mmol over 
24 hrs 
MgSO4 does not re-
duce chance of 
death / disability 
significantly post-
stroke 
Mirrahimi et al., 
2015 
60 supratento-
rial craniot-
omy for 
brain tu-
mors 
5 g of MgSO4 in normal 
saline infused every 6 hrs 
2 days before surgery, 
then same dosage was 
repeated the day before 
and during surgery 
MgSO4 is safe and 
effective to reduce 
S100B protein in 
the serum 
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Study/References Study  
population 
no. of  
patients 
Associ-
ated  
Diseases 
MgSO4 dosage Outcome/results 
Muir and Lees, 
1995 
60 acute 
stroke 
8 mmol IV over 15 
minutes and 65 mmol 
over 24 hrs 
deleterious hemo-
dynamic effects 
were observed in 
the patients as well 
as no side effects 
Saver et al., 2015 1700 acute 
stroke 
bolus of 4 g of MgSO4 in 
54 ml of normal saline 
over a period of 15 
minutes, then 16 g of 
MgSO4 diluted in 240 ml 
of normal saline, 10 ml 
per h for 24 hrs 
MgSO4 is safe but 
did not improve dis-
ability outcome 90 
days post-stroke 
Singh et al., 2012 60 acute 
stroke 
4 g MgSO4 bolus dose 
over 15 min followed by 
16 g MgSO4 over the next 
24 hrs 
no significant 
change in stroke 
score 3 and 28 
days post-stroke 
Singh et al., 2008 60 acute 
asthma 
2 g loading dose over 
20 min 
concurrent use of 
MgSO4 with stand-
ard treatment im-
proves pulmonary 
function and dis-
charge rates 
Boonyavorakul et 
al., 2000 
33 acute 
asthma 
2 g loading dose MgSO4 did not im-
prove severity and 
admission rate in 
the patients 
Green and 
Rothrock, 1992 
120 acute 
asthma 
2 g loading dose over 
20 min 
MgSO4 did not alter 
outcome 
Silverman et al., 
2002 
248 acute 
asthma 
2 g loading dose over  
10–15 min 
MgSO4 improves 
pulmonary function 
as adjunctive treat-
ment 
Porter et al., 2001 42 acute 
asthma 
2 g loading dose over 
20 min 
MgSO4 did not de-
crease dyspnea or 
the hospital admis-
sion rate 
Scarfone et al., 
2000 
54 acute 
asthma 
75 mg/kg over 20 min 
(max 2.5 g) 
MgSO4 was not ef-
ficacious as adjunc-
tive treatment 
Ciarallo et al., 
1996 
31 acute 
asthma 
25 mg/kg over 20 min 
(max 2 g) 
MgSO4 improved in 
pulmonary function 
for short period of 
time without any 
significant alteration 
in systemic blood 
pressure 
Ciarallo et al., 
2000 
30 acute 
asthma 
40 mg/kg over 20 min 
(max 2 g) 
MgSO4 improved 
short-term pulmo-
nary function 
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Study/References Study  
population 
no. of  
patients 
Associ-
ated  
Diseases 
MgSO4 dosage Outcome/results 
Gurkan et al., 1999 20 acute 
asthma 
40 mg/kg over 20 min 
(max 2 g) 
MgSO4 was effec-
tive in the manage-
ment of acute 
asthma 
Devi et al., 1997 47 acute 
asthma 
100 mg/kg over 35 min earlier improvement 
in clinical signs and 
symptoms of 
asthma was ob-
served 
Bloch et al., 1995 135 acute 
asthma 
2 g loading dose over 
20 min 
MgSO4 decreased 
admission rate and 
improved FEV1 
Tiffany et al., 1993 48 acute 
asthma 
2 g loading dose over 
20 min followed by 2 g/h 
over 4 hrs 
MgSO4 was not ef-
ficacious as adjunc-
tive treatment 
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